Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cancer With A High Tumor Mutational Burden”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Study completedNCT03668119
What this trial is testing

Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Who this might be right for
Pan Tumor
Bristol-Myers Squibb 212
Testing effectiveness (Phase 2)WithdrawnNCT06331598
What this trial is testing

Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Who this might be right for
Solid Tumors
Hoffmann-La Roche
Testing effectiveness (Phase 2)Active Not RecruitingNCT05199272
What this trial is testing

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaEpithelial Ovarian Cancer+6 more
23andMe, Inc. 141
Testing effectiveness (Phase 2)Looking for participantsNCT06923761
What this trial is testing

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

Who this might be right for
Advanced Solid Malignancy
Grey Wolf Therapeutics 300
Testing effectiveness (Phase 2)UnknownNCT03638297
What this trial is testing

PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer

Who this might be right for
Colorectal Cancer
Sun Yat-sen University 29
Testing effectiveness (Phase 2)Looking for participantsNCT05592626
What this trial is testing

A Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsGenital Neoplasm, FemaleUrogenital Neoplasms+9 more
Marengo Therapeutics, Inc. 365
Large-scale testing (Phase 3)Looking for participantsNCT05770102
What this trial is testing

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Who this might be right for
MalignancyMalignant NeoplasmLymphoproliferative Disorders+7 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Testing effectiveness (Phase 2)Looking for participantsNCT06634875
What this trial is testing

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

Who this might be right for
Colorectal Cancer Metastatic
Buzzard Pharmaceuticals 20
Testing effectiveness (Phase 2)Study completedNCT03836066
What this trial is testing

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Fundación GECP 41
Testing effectiveness (Phase 2)Looking for participantsNCT06365840
What this trial is testing

IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

Who this might be right for
TMB-HHistologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
ImmuneOncia Therapeutics Inc. 30